OMIC — Singular Genomics Systems Share Price
0.000.00%
Last trade - 00:00- $20.19m
- -$120.66m
- $2.91m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.17 | ||
| Price to Tang. Book | 0.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.43 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -46.75% | ||
| Return on Equity | -48.47% | ||
| Operating Margin | -4187.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.77 | 2.91 | 2.4 | 11 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.
Directors
- Andrew Spaventa CHM (36)
- David Daly PRE (59)
- Eli Glezer FDR (52)
- Dalen Meeter SVF (43)
- Jorge Velarde SVP (54)
- Vincent Brancaccio VPR (38)
- Daralyn Durie GCN (53)
- Michael Pellini LED (55)
- David Barker IND (79)
- Andrew Elbardissi IND (39)
- Kim Kamdar IND (53)
- Elaine Mardis IND (58)
- Jason Ryan IND (47)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 3rd, 2016
- Public Since
- May 27th, 2021
- No. of Shareholders
- 63
- No. of Employees
- 255
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 74,092,970
- Address
- 3010 SCIENCE PARK ROAD, SAN DIEGO, 92121
- Web
- https://singulargenomics.com/
- Phone
- +1 8583337830
- Contact
- Philip Taylor
- Auditors
- Ernst & Young LLP
Upcoming Events for OMIC
Q2 2024 Singular Genomics Systems Inc Earnings Release
Similar to OMIC
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Singular Genomics Systems share price?
As of Today at 23:18 UTC, shares in Singular Genomics Systems are trading at $0.35. This share price information is delayed by 15 minutes.
How has the Singular Genomics Systems share price performed this year?
Shares in Singular Genomics Systems last closed at $0.35 and the price had moved by -56.99% over the past 365 days. In terms of relative price strength the Singular Genomics Systems share price has underperformed the S&P500 Index by -65.77% over the past year.
What are the analyst and broker recommendations for Singular Genomics Systems?
The overall consensus recommendation for Singular Genomics Systems is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Singular Genomics Systems dividend yield?
Singular Genomics Systems does not currently pay a dividend.
Does Singular Genomics Systems pay a dividend?
Singular Genomics Systems does not currently pay a dividend.
When does Singular Genomics Systems next pay dividends?
Singular Genomics Systems does not currently pay a dividend.
How do I buy Singular Genomics Systems shares?
To buy shares in Singular Genomics Systems you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Singular Genomics Systems?
As of the previous close price of $0.35, shares in Singular Genomics Systems had a market capitalisation of $25.96m.
Where are Singular Genomics Systems shares listed?
Here are the trading details for Singular Genomics Systems:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: OMIC
What kind of share is Singular Genomics Systems?
Based on an overall assessment of its quality, value and momentum Singular Genomics Systems is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Singular Genomics Systems share price forecast for 2024?
The analyst consensus target price for shares in Singular Genomics Systems is $0.75. That is 114.04% above the last closing price of $0.35.
Analysts covering Singular Genomics Systems currently have a consensus Earnings Per Share (EPS) forecast of -$1.19 for the next financial year.
What is the trend in the Singular Genomics Systems share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Singular Genomics Systems. Over the past six months, its share price has underperformed the S&P500 Index by -28.63%.
As of the last closing price of $0.35, shares in Singular Genomics Systems were trading -18.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Singular Genomics Systems PE Ratio?
The Singular Genomics Systems PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Singular Genomics Systems?
Singular Genomics Systems' management team is headed by:
- Andrew Spaventa - CHM
- David Daly - PRE
- Eli Glezer - FDR
- Dalen Meeter - SVF
- Jorge Velarde - SVP
- Vincent Brancaccio - VPR
- Daralyn Durie - GCN
- Michael Pellini - LED
- David Barker - IND
- Andrew Elbardissi - IND
- Kim Kamdar - IND
- Elaine Mardis - IND
- Jason Ryan - IND